Free CPD Education: AndroFeme 1 Guide for Prescribers + Diagnose & Manage HSDD Banner

Free CPD Education: AndroFeme 1 Guide for Prescribers + Diagnose & Manage HSDD

Categories:

Empower Your Practice: Address HSDD with Confidence – Now with Androfeme 1 Insights

Hypoactive Sexual Desire Disorder (HSDD) is a common yet often under-recognised concern in general practice—particularly among postmenopausal women. This CPD-approved education from Praxhub combines two essential modules to support your clinical expertise:

✔️ Diagnose & Manage HSDD
Gain a comprehensive, evidence-based approach to assessing and managing HSDD in the Australian clinical setting.

  • Identify biological, psychological, and interpersonal factors
  • Use validated screening tools for accurate diagnosis
  • Explore diverse management options

✔️ AndroFeme 1: A Guide for Prescribers
Learn practical prescribing guidance for testosterone therapy in women, including safety, dosing, and monitoring.

⏱ 30-minute modules | Earn up to 2.5 CPD hours

Join now to enhance your confidence and make a meaningful impact on your patients’ quality of life.

👉 Register today to upskill in HSDD care and prescribing AndroFeme 1.

 

 

Latest News


Reasons for PBAC denial of women’s testosterone therapy released: “inequitable” and “scientifically flawed” Reasons for PBAC denial of women’s testosterone therapy released: “inequitable” and “scientifically flawed”

MEDIA RELEASE – Embargo 12.00 am, 27 March 2026 Reasons for PBAC denial of women’s testosterone therapy released: “inequitable” and “scientifically flawed” Last Friday,… Continue Reading →

AUSTRALIAN MINNOW, LAWLEY PHARMACEUTICALS, TAKES PBAC TO FEDERAL COURT AUSTRALIAN MINNOW, LAWLEY PHARMACEUTICALS, TAKES PBAC TO FEDERAL COURT

MEDIA RELEASE – Wed 11 February 2026 AUSTRALIAN MINNOW, LAWLEY PHARMACEUTICALS, TAKES PBAC TO FEDERAL COURT A small Perth-based pharmaceutical company is stepping up… Continue Reading →